This article is more than 5 years old. Information may no longer be current.

Bacterial conjunctivitis drug performed well in phase 2 study

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ALAMEDA, Calif. — Azithromycin has shown positive results in a phase 2 clinical trial for the treatment of bacterial conjunctivitis, according to the company developing the drug for ophthalmic purposes.

ISV-401 elicited both clinical resolution and bacterial eradication over both gram-positive and gram-negative strains of acute bacterial conjunctivitis, according to a news release from InSite Vision. During the phase 2 trial, six drops of ISV-401 were administered over 5 consecutive days. That treatment regimen produced comparable clinical results in treating acute bacterial conjunctivitis seen with more than 35 drops of currently marketed drugs, the company noted.

The company plans on initiating a phase 3 trial in early 2003.